U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C26H31Cl2N7O3
Molecular Weight 560.4763
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of INFIGRATINIB

SMILES

CCN1CCN(CC1)c2ccc(cc2)Nc3cc(ncn3)N(C)C(=Nc4c(c(cc(c4Cl)OC)OC)Cl)O

InChI

InChIKey=QADPYRIHXKWUSV-UHFFFAOYSA-N
InChI=1S/C26H31Cl2N7O3/c1-5-34-10-12-35(13-11-34)18-8-6-17(7-9-18)31-21-15-22(30-16-29-21)33(2)26(36)32-25-23(27)19(37-3)14-20(38-4)24(25)28/h6-9,14-16H,5,10-13H2,1-4H3,(H,32,36)(H,29,30,31)

HIDE SMILES / InChI

Molecular Formula C26H31Cl2N7O3
Molecular Weight 560.4763
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: http://adisinsight.springer.com/drugs/ | DOI: 10.1158/2159-8290.CD-NB2014-057 | http://meetinglibrary.asco.org/content/159420-173

Infigratinib (BGJ398), a potent, orally bioavailable, small-molecule pan-FGFR kinase inhibitor. FGFR genetic alterations are the most significant predictors for BGJ398 sensitivity. It is currently in phase 2 trials for Cholangiocarcinoma, Glioblastoma and Solid tumors. Detected adverse events were hyperphosphatemia, fatigue, constipation, cough and nausea. Other adverse events were generally mild and included stomatitis, hair loss, decreased appetite, and fatigue.

Originator

Curator's Comment:: # Novartis

Approval Year

PubMed

PubMed

TitleDatePubMed
Inhibition of FGF Signalling Pathway Augments the Expression of Pluripotency and Trophoblast Lineage Marker Genes in Porcine Parthenogenetic Blastocyst.
2016 Oct
Patents

Sample Use Guides

1 x 100 mg and 1 x 25 mg capsules once daily for the first 21 days of the 28-day cycle (3 weeks on, 1 week off in a cycle).
Route of Administration: Oral
BGJ398 inhibits the proliferation of the FGFR1-, FGFR2-Q, and FGFR3-dependent BaF3 cells with IC50 of 2.9 μM, 2.0 μM and 2 μM, respectively. BGJ398 interferes with autophosphorylation on specific tyrosine residues including FGFR-WT, FGFR2-WT, FGFR3-K650E, FGFR3-S249C and FGFR4-WT with IC50 of 4.6 nM, 4.9 nM, 5 nM, 5 nM and 168 nM, respectively. BGJ398 suppresses proliferation of the cancer cells with wild-type (WT) FGFR3 overexpression such as RT112, RT4, SW780 and JMSU1 with IC50 of 5 nM, 30 nM, 32 nM and 15 nM, respectively.
Substance Class Chemical
Created
by admin
on Sat Jun 26 05:15:54 UTC 2021
Edited
by admin
on Sat Jun 26 05:15:54 UTC 2021
Record UNII
A4055ME1VK
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
INFIGRATINIB
INN   WHO-DD  
INN   USAN  
Official Name English
UREA, N'-(2,6-DICHLORO-3,5-DIMETHOXYPHENYL)-N-(6-((4-(4-ETHYL-1-PIPERAZINYL)PHENYL)AMINO)-4-PYRIMIDINYL)-N-METHYL-
Systematic Name English
BGJ398
Code English
INFIGRATINIB [USAN]
Common Name English
3-(2,6-DICHLORO-3,5-DIMETHOXYPHENYL)-1-(6-((4-(4-ETHYLPIPERAZIN-1-YL)PHENYL)AMINO)PYRIMIDIN-4-YL)-1-METHYLUREA
Systematic Name English
BGJ-398
Code English
INFIGRATINIB [INN]
Common Name English
INFIGRATINIB [WHO-DD]
Common Name English
NVP-BGJ398
Code English
N'-(2,6-DICHLORO-3,5-DIMETHOXYPHENYL)-N-(6-((4-(4-ETHYL-1- PIPERAZINYL)PHENYL)AMINO)-4-PYRIMIDINYL)-N-METHYLUREA
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C1742
Created by admin on Sat Jun 26 05:15:54 UTC 2021 , Edited by admin on Sat Jun 26 05:15:54 UTC 2021
NCI_THESAURUS C129825
Created by admin on Sat Jun 26 05:15:54 UTC 2021 , Edited by admin on Sat Jun 26 05:15:54 UTC 2021
FDA ORPHAN DRUG 707019
Created by admin on Sat Jun 26 05:15:54 UTC 2021 , Edited by admin on Sat Jun 26 05:15:54 UTC 2021
NCI_THESAURUS C1967
Created by admin on Sat Jun 26 05:15:54 UTC 2021 , Edited by admin on Sat Jun 26 05:15:54 UTC 2021
Code System Code Type Description
FDA UNII
A4055ME1VK
Created by admin on Sat Jun 26 05:15:54 UTC 2021 , Edited by admin on Sat Jun 26 05:15:54 UTC 2021
PRIMARY
ChEMBL
CHEMBL1852688
Created by admin on Sat Jun 26 05:15:54 UTC 2021 , Edited by admin on Sat Jun 26 05:15:54 UTC 2021
PRIMARY
PUBCHEM
53235510
Created by admin on Sat Jun 26 05:15:54 UTC 2021 , Edited by admin on Sat Jun 26 05:15:54 UTC 2021
PRIMARY
INN
10032
Created by admin on Sat Jun 26 05:15:54 UTC 2021 , Edited by admin on Sat Jun 26 05:15:54 UTC 2021
PRIMARY
DRUG BANK
DB11886
Created by admin on Sat Jun 26 05:15:54 UTC 2021 , Edited by admin on Sat Jun 26 05:15:54 UTC 2021
PRIMARY
EPA CompTox
872511-34-7
Created by admin on Sat Jun 26 05:15:54 UTC 2021 , Edited by admin on Sat Jun 26 05:15:54 UTC 2021
PRIMARY
NCI_THESAURUS
C88302
Created by admin on Sat Jun 26 05:15:54 UTC 2021 , Edited by admin on Sat Jun 26 05:15:54 UTC 2021
PRIMARY
CAS
872511-34-7
Created by admin on Sat Jun 26 05:15:54 UTC 2021 , Edited by admin on Sat Jun 26 05:15:54 UTC 2021
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
TARGET -> INHIBITOR
TARGET -> INHIBITOR
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY